Humanized Anti-Tau Antibody Epitope Selection for Blood-Brain Barrier Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments for tauopathies, which are neurodegenerative diseases characterized by the pathological aggregation of tau protein, and there is a need for specific reagents to address these conditions.
Innovation Solution
Development of a humanized monoclonal antibody that specifically binds to an epitope within amino acids 15-24 of the Tau polypeptide, competing with existing antibodies for binding to the N-terminal region of the Tau protein, and is formulated to cross the blood-brain barrier for effective treatment and monitoring of tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies are used to treat tauopathies, then some binding to tau protein is achieved, but they fail to effectively cross the blood-brain barrier and reduce pathological tau aggregation
Solution Approach 1:
The antibody structure is modified by humanization to change its biochemical parameters, specifically improving its ability to cross the blood-brain barrier while maintaining affinity for the tau epitope. This involves changing the antibody's origin from non-human to humanized to reduce immunogenicity and improve BBB penetration.
Solution Approach 2:
The patent uses an intermediary approach by selecting a specific linear epitope (amino acids 15-24) in the N-terminal region of tau that is accessible and suitable for antibody binding. This epitope selection acts as an intermediary step to enable effective therapeutic action while overcoming the limitations of previous antibodies.
2Measurement precision
If antibodies bind to phosphorylated or nitrated amino acids in tau, then they may recognize pathological forms, but they risk cross-reactivity and reduced specificity
Solution Approach 1:
The antibody is designed to bind to a specific local region (amino acids 15-24) of the tau protein with high precision. This localized binding to a non-phosphorylated, non-nitrated epitope ensures high specificity for tau while avoiding cross-reactivity with other proteins that may have similar phosphorylated or nitrated residues.
3Productivity
If no effective treatment methods exist for tauopathies, then current therapeutic options are limited, but developing new treatments requires extensive research and validation
Solution Approach 1:
The patent performs preliminary actions by identifying and characterizing a specific epitope (amino acids 15-24) before full therapeutic development. This preliminary epitope selection and antibody design provide a head start in the therapeutic development process, reducing the overall time required to bring an effective treatment to market.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody reduces the levels of pathological tau in the brain, decreases neuron-to-neuron spread of tau, and decreases microglial and astrocyte activation, thereby alleviating symptoms and slowing disease progression in tauopathies.
Implementation Method 1
an isolated humanized monoclonal antibody that specifically binds an epitope within amino acids 15-24 of a Tau polypeptide
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.